alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
* Pursuant to 5TH CIR. R. 47.5, the court has determined that this opinion

should not be published and is not precedent except under the limited

circumstances set forth in 5TH CIR. R. 47.5.4.

United States Court of Appeals

Fifth Circuit

FILED

August 21, 2007

Charles R. Fulbruge III

Clerk

IN THE UNITED STATES COURT OF APPEALS

FOR THE FIFTH CIRCUIT

No. 06-20986

Conference Calendar

UNITED STATES OF AMERICA

Plaintiff-Appellee

v.

AMIN ALI NAZARALLY, also known as Antonio Villareal

Defendant-Appellant

Appeal from the United States District Court

for the Southern District of Texas

USDC No. 4:06-CR-35-ALL

Before HIGGINBOTHAM, SMITH, and CLEMENT, Circuit Judges.

PER CURIAM:*

Amin Ali Nazarally appeals his guilty-plea conviction and 57-month

sentence for illegal reentry, in violation of 8 U.S.C. § 1326. He argues that his

sentence is unreasonable as a matter of law because this court’s use of a

presumption of reasonableness for sentences imposed within the properly

calculated guidelines range effectively reinstates the mandatory guidelines

regime struck down in UnitedStates v. Booker, 543 U.S. 220 (2005). He concedes
No. 06-20986

2

that the argument is foreclosed by circuit precedent, but he raises it to preserve

it for further review. The argument fails as the Supreme Court has since

affirmed the use of a presumption of reasonableness. Rita v. United States,

127 S. Ct. 2456, 2462-66 (2007). 

Nazarally’s constitutional challenge to § 1326(b) is foreclosed by

Almendarez-Torres v. United States, 523 U.S. 224, 235 (1998). Although

Nazarally contends that Almendarez-Torres was incorrectly decided and that a

majority of the Supreme Court would overrule Almendarez-Torres in light of

Apprendi v. New Jersey, 530 U.S. 466 (2000), we have repeatedly rejected such

arguments on the basis that Almendarez-Torres remains binding. See United

States v. Garza-Lopez, 410 F.3d 268, 276 (5th Cir. 2005); see also Rangel-Reyes

v. United States, 126 S. Ct. 2873 (2006); United States v. Pineda-Arrellano, 2007

U.S. App. LEXIS 16925 (5th Cir. July 17, 2007). Nazarally properly concedes

that his argument is foreclosed in light of Almendarez-Torres and circuit

precedent, but he raises it here to preserve it for further review.

AFFIRMED.
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[S. 334 Engrossed in Senate (ES)]

  1st Session
                                 S. 334

_______________________________________________________________________

                                 AN ACT

 
   To amend the Federal Power Act to remove the jurisdiction of the 
   Federal Energy Regulatory Commission to license projects on fresh 
                     waters in the State of Hawaii.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. PROJECTS ON FRESH WATERS IN THE STATE OF HAWAII.

    Section 4(e) of the Federal Power Act (16 U.S.C. 797(e)) is amended 
in the first sentence by striking ``several States, or upon'' and 
inserting ``several States (except fresh waters in the State of Hawaii, 
unless a license would be required under section 23), or upon''.

            Passed the Senate March 25, 1999.

            Attest:

                                                             Secretary.
106th CONGRESS

  1st Session

                                 S. 334

_______________________________________________________________________

                                 AN ACT

   To amend the Federal Power Act to remove the jurisdiction of the 
   Federal Energy Regulatory Commission to license projects on fresh 
                     waters in the State of Hawaii.
```
[Federal Register Volume 89, Number 205 (Wednesday, October 23, 2024)]
[Notices]
[Page 84664]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-24485]


-----------------------------------------------------------------------

SMALL BUSINESS ADMINISTRATION

[Disaster Declaration #20711 and #20712; GEORGIA Disaster Number GA-
20013]


Presidential Declaration Amendment of a Major Disaster for the 
State of Georgia

AGENCY: Small Business Administration.

ACTION: Amendment 7.

-----------------------------------------------------------------------

SUMMARY: This is an amendment of the Presidential declaration of a 
major disaster for the State of Georgia (FEMA-4830-DR), dated 09/30/
2024.
    Incident: Hurricane Helene.
    Incident Period: 09/24/2024 and continuing.

DATES: Issued on 10/16/2024.
    Physical Loan Application Deadline Date: 11/29/2024.
    Economic Injury (EIDL) Loan Application Deadline Date: 06/30/2025.

ADDRESSES: Visit the MySBA Loan Portal at https://lending.sba.gov to 
apply for a disaster assistance loan.

FOR FURTHER INFORMATION CONTACT: Alan Escobar, Office of Disaster 
Recovery & Resilience, U.S. Small Business Administration, 409 3rd 
Street SW, Suite 6050, Washington, DC 20416, (202) 205-6734.

SUPPLEMENTARY INFORMATION: The notice of the President's major disaster 
declaration for the State of Georgia, dated 09/30/2024, is hereby 
amended to include the following areas as adversely affected by the 
disaster:

Primary Counties (Physical Damage and Economic Injury Loans): 
Taliaferro.

    All other information in the original declaration remains 
unchanged.

(Catalog of Federal Domestic Assistance Number 59008)

Rafaela Monchek,
Deputy Associate Administrator, Office of Disaster Recovery & 
Resilience.
[FR Doc. 2024-24485 Filed 10-22-24; 8:45 am]
BILLING CODE 8026-09-P
<PAGE>

                                                                   EXHIBIT 23.1

                        CONSENT OF INDEPENDENT AUDITORS

The Board of Directors
Pilot Network Services, Inc.:

We consent to the incorporation by reference in the registration statement
(No. 333-61187) on Form S-8 of Pilot Network Services, Inc. of our report
dated April 28, 1999, relating 1998 to the consolidated balance sheets of
Pilot Network Services, Inc. and subsidiary as of March 31, 1998 and 1999 and
the related consolidated statements of operations, comprehensive loss,
stockholders' equity (deficit) and cash flows for each of the years in the
three-year period ended march 31, 1999, and related schedule, which report
appears in the March 31 ,1999, annual report on Form 10-K of Pilot Network
Services, Inc.

                                          /s/ KPMG LLP

San Francisco, California
June 29, 1999
Exhibit 32.1  CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350  In connection with this Quarter Report of China Northern Medical Device, Inc.  (the Company) on Form 10-Q for the period ending June 30, 2011, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Jinzhao Wu, Chief Executive Officer and Chief Financial Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec. 906 of the Sarbanes-Oxley Act of 2002, that:  1.Such Quarter Report on Form 10-Q for the period ending June 30, 2011, fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  2.The information contained in such Quarter Report on Form 10-Q for the period ending June 30, 2011, fairly presents, in all material respects, the financial condition and results of operations of China Northern Medical Device, Inc.  Date:   August 15, 2011/s/Jinzhao WuJinzhao Wu
Chief Executive Officer
Chief Financial Officer
**Exhibit32.1**

**CERTIFICATIONPURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATESCODE**

Pursuant tosection 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section1350, chapter 63 of Title 18, United States Code), the undersigned officers ofCorgenix Medical Corporation, a Nevada corporation (the “Company”), does herebycertify with respect to the Annual Report of the Company on Form 10-KSB for theyear ended June 30, 2007 as filed with the Securities an Exchange Commission(the “10-KSB Report”) that:

i.                     the10-KSB Report fully complies with the requirements of section 13(a) or 15(d) ofthe Securities Exchange Act of 1934; and

ii.                  the information contained in the 10-KSB Report fairlypresents, in all material respects, the financial condition and results ofoperations of the Company.

Dated:                 September 14, 2007

**ThisCertification is made solely for purposes of 18 U.S.C. Section 1350, subject tothe knowledge standard contained therein, and not for any other purpose.**

**A signedoriginal of this written statement required by Section 906 of theSarbanes-Oxley Act has been provided to the Company and will be retained by theCompany and furnished to the Securities and Exchange Commission or its staffupon request. This written statement shall not be deemed to be “filed” as partof the annual report on Form 10-KSB that it accompanies.**
| /S/Douglass T. Simpson                |   |
|---------------------------------------|--------|
| President and Chief Executive Officer |

 

----
Federal Register / Vol. 89, No. 205 / Wednesday, October 23, 2024 / Notices 84611 

Dated: October 18, 2024. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2024–24565 Filed 10–22–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel; Interaction between ARVs 

and Hormones in HIV and Coinfections (R01 

Clinical Trial Optional). 

Date: November 19, 2024. 

Time: 10:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute of Allergy and 

Infectious Diseases, National Institutes of 

Health, 5601 Fishers Lane, Room 3G34, 

Rockville, MD 20892 (Video Assisted 

Meeting). 

Contact Person: Vishakha Sharma, Ph.D., 

Scientific Review Officer, Scientific Review 

Program, Division of Extramural Activities, 

National Institute of Allergy and Infectious 

Diseases, National Institutes of Health, 5601 

Fishers Lane, Room 3G34, Rockville, MD 

20892, 301–761–7036, vishakha.sharma@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: October 18, 2024. 

Lauren A. Fleck, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2024–24542 Filed 10–22–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Transportation Security Administration 

[Docket No. TSA–2018–0001] 

Surface Transportation Security 

Advisory Committee; Meeting 

AGENCY: Transportation Security 

Administration, Department of 

Homeland Security. 

ACTION: Committee management; Notice 

of open Federal advisory committee 

meeting. 

SUMMARY: The Transportation Security 

Administration (TSA) will hold a 

meeting of the Surface Transportation 

Security Advisory Committee (STSAC) 

on November 21, 2024. Members of the 

public will be able to participate 

virtually via Microsoft Teams. The 


khammond on DSKJM1Z7X2PROD with NOTICESEN23OC24.006</GPH>

Tixocortol Pivala:~g 

Potentially repurpoJ~d 

forSARS-Co 

SARS-COV•2 

Tixocortol Pivalate 

Prodrug 

0 

OH 0 ~OHO C OH HS H e S-S . HI 

l H . i 

-'"+~ I•, o 

0 

Tixocortol Tixocortol dfsulp hide
```

[Congressional Bills 106th Congress]
[From the U.S. Government Publishing Office]
[S. 340 Introduced in Senate (IS)]

106th CONGRESS
  1st Session
                                 S. 340

   To amend the Cache La Poudre River Corridor Act to make technical 
                  corrections, and for other purposes.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            February 3, 1999

  Mr. Allard introduced the following bill; which was read twice and 
       referred to the Committee on Energy and Natural Resources

_______________________________________________________________________

                                 A BILL

 
   To amend the Cache La Poudre River Corridor Act to make technical 
                  corrections, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CACHE LA POUDRE RIVER CORRIDOR.

    Section 103(b) of the Cache La Poudre River Corridor Act (16 U.S.C. 
461 note, Public Law 104-323) is amended in paragraphs (12) through 
(19), by striking ``larimer county'' each place it appears and 
inserting ``weld county''.

SEC. 2. CACHE LA POUDRE RIVER CORRIDOR COMMISSION.

    Section 104 of the Cache La Poudre River Corridor Act (16 U.S.C. 
461 note, Public Law 104-323) is amended--
            (1) by striking subsection (a) and inserting the following:
    ``(a) In General.--There is established a commission to be known as 
the `Cache La Poudre Corridor Commission' that shall--
            ``(1) administer the Corridor; and
            ``(2) provide certain services under this Act.''; and
            (2) in subsection (b)(1)(A)(v)(III), by striking ``within'' 
        and inserting ``in the vicinity of''.
                                 <all>
```
COURT OF APPEALS

SECOND DISTRICT OF TEXAS

FORT WORTH

NO. 02-12-00186-CV

SHANE GORDON AND JENNIFER 

GORDON

APPELLANTS

V.

DARWIN NEAL TRAHERN AND 

DEBORAH TRAHERN

APPELLEES

------------

FROM THE 271ST DISTRICT COURT OF WISE COUNTY

------------

MEMORANDUM OPINION1 AND JUDGMENT

------------

On July 11, 2012, we notified appellants that the trial court clerk 

responsible for preparing the record in this appeal informed the court that 

payment arrangements had not been made to pay for the clerk’s record as 

required by Texas Rule of Appellate Procedure 35.3(a)(2). See Tex. R. App. P. 

35.3(a)(2). We stated that we would dismiss the appeal for want of prosecution 

 

1See Tex. R. App. P. 47.4.
2

unless appellants, within ten days, made arrangements to pay for the clerk’s 

record and provided this court with proof of payment. 

Because appellants have not made payment arrangements for the clerk’s 

record, it is the opinion of the court that the appeal should be dismissed for want 

of prosecution. Accordingly, we dismiss the appeal. See Tex. R. App. P. 

37.3(b), 42.3(b).

Appellants shall pay all costs of the appeal, for which let execution issue.

PER CURIAM

PANEL: GABRIEL, J.; LIVINGSTON, C.J.; and DAUPHINOT, J.

DELIVERED: October 11, 2012
EXHIBIT 32.1



CERTIFICATION PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C SECTION 1350)



In connection with the Annual Report of
Dominion Minerals Corp. (the “Company”) on Form 10-Q for the period ending June 30, 2017 as filed with the Securities
and Exchange Commission (the “Report”), Pinchas Althaus, the Chief Executive Officer of the Company, certifies, pursuant
to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of the Company.
| | --- | --------------------------------------------------------------------------------------------------------------------------------------



|Date: August 24, 2017 | By: | /s/ Pinchas Althaus    
|--------------------- | --- | -----------------------
|                      |     | Pinchas Althaus        
|                      |     | Chief Executive Officer
|                      |     |
STRUCTURE ACTIVITY TEAM REPORT 09/09/03 

CASE NUMBER: P03-0793

RELATED CASES: 

CONCLUSIONS/DISCUSSIONS 

TYPE OF CONCERN: HEALTH ECOTOX 

LEVEL OF CONCERN: 2 3 

KEYWORDS: CORR-E,S,MM,L 

 AQUATOX 

SUMMARY OF ASSESSMENT 

FATE: Estimations for hydrolysis product diethylamine 

LogKow = 0.58(M); LogKoc = 1.66(E); LogBCF = 0.50(E); 

 Estimations for hydrolysis product ethanol 

LogKow = -0.31(M); LogKoc = 0.00(E); LogBCF = 0.50(E); 

PMN Substance: Liquid 

S = Reacts(E, 25 EC); H < 1.00E-8(E) 

MP (C) < 20(E); BP (C) = 191(M); VP @ 25C (mm) = 0.54(NOMO5) 

POTW removal (%) = 99 via hydrolysis then 90 via biodeg 

Time for complete ultimate aerobic biodeg = da-wk 

PBT Potential: P1B1T1 

Hydrolysis Halflife: SiN = min-hr; SiOEt = da (Analogs) 

For the DEA & ethanol hydrolysis products 

Sorption to soils/sediments = low 

*CEB FATE: Migration to ground water = negl - slow 

Volatilization Halflife DEA;EtOH Rivers(hr) = 20;80 

 Lakes(da) = 12;39 

Atmospheric Oxidation Halflife (hr) DEA;EtOH OH = 1.6;36 

HEALTH: Absorbed with reaction all routes (pchem). Concern for 

to all tissues based on the reactivity of the PMN substance and 

on the submitted acute test data. 

 *CEB HEALTH: Moderate concern (Dermal, inhalation) 

 Test data: (-) Salmonella with and without activation; (-) 

E. coli with and without activation; (-) for chromosome 

aberrations in CHL cells with and without activation; rat oral 

LD50 between 500 and 1000 mg/kg (signs of to GI tract) 
ECOTOX: Predicted (P) and measured (M) toxicity values in mg/L 

(ppm) are: 

fish 96-h LC50 = 590.0 P 

daphnid 48-h LC50 = 36.0 P 

green algal 96-h EC50 < 1.0 P 

fish chronic value (ChV) = 60.0 P 

daphnid ChV = 4.0 P 

green algal ChV <= 0.100 P 

Predictions were based on SAR-nearest analog method for 

alkoxysilanes and SARs for aliphatic amines; SAR chemical 

class: alkoxysilanes-silamine; MW235; log Kow = 0.50 (EPI); 

effective concentrations based on 100 percent active ingredients 

and nominal concentrations; hardness <180 mg/L as CaCO3; pH7; 

high concern for toxicity; 

AsF = 10.0 

concern concentration = 0.010 mg/L (ppm) 

*CEB ECOTOX: All releases to water for the parent material and 

the hydrolysis product(s) 

SAT Co-chair: Leonard Keifer 564-8916
# Fourth Court of Appeals

**San Antonio, Texas**

JUDG MENT

No. 04

- 18

- 00554

- CV

MO

- VAC COMPANY OF AL ICE

, Appellant

v.

MICHAEL MYANE LP d/b/a Pipeline Measurement Co., LP and Michael Myane Management, LLC, Appellees

From the 79th Judicial District Court, Jim Wells County, Texas

Trial Court No. 15

- 04

- 54479

- CV Honorable Richard C. Terrell, Judge Presiding

BEFORE CHIEF JUSTICE MARION

, JUSTICE WATKINS , AND JUSTICE RODRIGUEZ

In accordance with this court’s opinion of this date, the joint motion filed by the parties is GRANTED, and judgment is RENDERED vacating the trial court’s judgment signed on May 14, 2018 and dismissing the cause in accordance with the parties’ settlement agreement.

We order that appellant and appellee each bear their own costs of this appeal, if any.

SIGNED May 22, 2019.

_________________________________ Beth Watkins , Justice
Michigan Supreme Court

Lansing, Michigan

Robert P. Young, Jr.,

 Chief Justice

Michael F. Cavanagh

Marilyn Kelly

Stephen J. Markman

Diane M. Hathaway

Mary Beth Kelly

Brian K. Zahra, Justices

I, Corbin R. Davis, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

 _________________________________________ 

 Clerk

February 1, 2012 

t0125 

Order 

 

February 1, 2012 

143645 

THOMAS M. KOHLOFF, 

Plaintiff-Appellee, 

v SC: 143645 

 COA: 300801 

WCAC: 08-000185 

CHRYSLER GROUP, L.L.C., f/k/a 

DAIMLERCHRYSLER CORPORATION, 

Defendant-Appellant. 

_________________________________________/ 

 On order of the Court, the application for leave to appeal the July 19, 2011 order 

of the Court of Appeals is considered and, pursuant to MCR 7.302(H)(1), in lieu of 

granting leave to appeal, we REMAND this case to the Court of Appeals for 

consideration as on leave granted.
EXHIBIT 3



CEO CERTIFICATION OF ANNUAL FILINGS



Form 52-109F1

Certification of Annual Filings



I, Steve Manz, CEO of Freegold Ventures Limited certify that:



1.

I have reviewed the annual filings (as this term is defined in Multilateral Instrument 52-109 Certification of Disclosure in Issuers Annual and Interim Filings) of Freegold Ventures Limited for the period ending December 31, 2007;



2.

Based on my knowledge, the annual filings do not contain any untrue statement of a material fact or omit to state a material fact required to be stated or that is necessary to make a statement not misleading in light of the circumstances under which it was made, with respect to the period covered by the annual filings;



3.

Based on my knowledge, the annual financial statements together with the other financial information included in the annual filings fairly present in all material respects the financial condition, results of operations and cash flows of the issuer, as of the date and for the periods presented in the annual filings;



4.

The issuers other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures and internal control over financial reporting for the issuer, and we have:



(a)

designed such disclosure controls and procedures, or caused them to be designed under our supervision, to provide reasonable assurance that material information relating to the issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which the annual filings are being prepared;



(b)

designed such internal control over financial reporting, or caused it to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with the issuers GAAP; and



(c)

evaluated the effectiveness of the issuers disclosure controls and procedures as of the end of the period covered by the annual filings and have caused the issuer to disclose in the annual MD&A our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by the annual filings based on such evaluation; and



5.

I have caused the issuer to disclose in the annual MD&A any change in the issuers internal control over financial reporting that occurred during the issuers most recent interim period that has materially affected, or is reasonably likely to materially affect, the issuers internal control over financial reporting.



DATED:

March 28, 2008





Per:

Steve Manz



Steve Manz

Chief Executive Officer



1